ID   RST2
AC   CVCL_5I55
DR   cancercelllines; CVCL_5I55
DR   Kerafast; EH0001
DR   Wikidata; Q54951344
RX   PubMed=19687011;
CC   Population: African; Kenyan.
CC   Characteristics: Resistant to the various effects of interferon-alpha (PubMed=19687011).
CC   Characteristics: Expresses a STAT2 mRNA with an alternative splice site between exon 19 and 20 that causes STAT2 translation termination at the beginning of the SH2 domain (PubMed=19687011).
CC   Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Met1Ile (c.3G>C); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala5_Ala80del (c.14_241del228); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0008 ! Daudi
SX   Male
AG   16Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 10-09-24; Version: 18
//
RX   PubMed=19687011; DOI=10.1074/jbc.M109.028324; PMCID=PMC2788831;
RA   Du Z.-Y., Fan M.-Y., Kim J.-G., Eckerle Mize D.L., Lothstein L., Wei L.,
RA   Pfeffer L.M.;
RT   "Interferon-resistant Daudi cell line with a Stat2 defect is resistant
RT   to apoptosis induced by chemotherapeutic agents.";
RL   J. Biol. Chem. 284:27808-27815(2009).
//